We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Bu'Hussain
Hayee
b.hayee@nhs.net
Alena
Marynina
alena.marynina@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
Benign neoplasmsMalignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
The early detection (screening) of bowel cancer represents a significant health challenge. Colonoscopy, a flexible camera examination of the large bowel (the gold standard test), requires training to perform comfortably and to a high enough standard to detect adenomas (polyps; pre-cancerous growths). The demand for high quality colonoscopy is rising as the demand for bowel cancer screening rises.
Adenoma detection rate (ADR) is the % number of colonoscopies performed where at least one adenoma is found. It is a widely accepted quality measure units worldwide. We do not have a good estimate of the average ADR across the UK, but it is likely to be < 20%. Expert colonoscopists in the national bowel cancer screening programme (< 2% of the total workforce in the UK) typically have ADR > 35%, but > 10x more colonoscopies in 'at risk' patients are performed outside of this system, in the "two-week-wait" referral pathway. We urgently need to evaluate technologies that can produce rapid and significant improvements in performance, across as wide a range of colonoscopists as possible.
The most intriguing of these is artificial intelligence (or computer assisted detection: CADe). This is a computer system in a box that is plugged into existing colonoscopy equipment and highlights polyps on the video screen. The GI Genius (GIG) system from Medtronic is advantageous as it is compatible with any colonoscopy equipment and can be used straight away.
We know GIG improves ADR in 'expert' colonoscopists with ADRs that are already well above average, but we do not yet know whether this applies to colonoscopists with varying levels of performance. We will therefore study the effect of implementing GIG into 'real-world' practice. We will study performance before, during and after GIG to fully understand whether and how it works.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Device;
You can take part if:
You may not be able to take part if:
Participants unable to provide written, informed consent. As this is a large, multicentre study, we can only provide patient information in English, but would rely on local provision for interpreter services to allow local research teams to recruit appropriate patients.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Bu'Hussain
Hayee
b.hayee@nhs.net
Alena
Marynina
alena.marynina@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 56972
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
